RodolfoEduardoBordoniMD

Oncology • Atlanta, GA

Physician

Join to view full profile

Are you Dr. Bordoni?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1100 Johnson Ferry Rd
Ste 600
Atlanta, GA 30342
Phone+1 404-256-4777

Fax+1 404-256-5515

Summary

Dr. Rodolfo Bordoni, MD is an oncologist in Atlanta, Georgia. He is currently licensed to practice medicine in Georgia and Texas. He is affiliated with Northside Hospital, WellStar Kennestone Hospital, and WellStar Cobb Hospital.

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1985 - 1988
Universidad Nacional de Rosario Faculty of MedicineClass of 1977

Certifications & Licensure

GA State Medical License 1988 - 2025
TX State Medical License 1991 - 1992

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013

Clinical Trials

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29
Terminated
Phase 2
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Start of enrollment: 2019 Nov 05
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

9 citations
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Jonathan W Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt
Blood. 2024-02-29
3 citations
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Amer M Zeidan, Rachel J Cook, Rodolfo Bordoni, James R Berenson, William J Edenfield
Clinical Lymphoma, Myeloma & Leukemia. 2022-07-01
236 citations
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Makoto Nishio, Fabrice Barlesi, Howard Jack West, Simon Ball, Rodolfo Bordoni
Journal of Thoracic Oncology. 2021-04-01